Checkpoint Capital L.P. Biotechnology

Checkpoint Capital L.P.

Stock	Market Cap.	Holding Value (Reported)	# of Shares.	Last Trade
ARGX Argenx Se	$34.6B	$50.1 Billion 24.88% of portfolio	92,500	Q3 2024 Added 12.6%
RYTM Rhythm Pharmaceuticals, Inc.	$3.15B	$34.8 Billion 17.24% of portfolio	663,381	Q3 2024 Reduced 28.06%
PHAT Phathom Pharmaceuticals, Inc.	$317M	$27.2 Billion 13.49% of portfolio	1,504,307	Q3 2024 Added 71.92%
CYTK Cytokinetics Inc	$4.46B	$24.6 Billion 12.23% of portfolio	466,813	Q3 2024 Added 145.69%
AXSM Axsome Therapeutics, Inc.	$3.77B	$18.8 Billion 9.35% of portfolio	209,632	Q3 2024 Reduced 27.91%
PTGX Protagonist Therapeutics, Inc	$1.94B	$10.8 Billion 5.36% of portfolio	240,000	Q3 2024 Reduced 32.39%
PLRX Pliant Therapeutics, Inc.	$683M	$4.26 Billion 2.11% of portfolio	380,000	Q3 2024 Added 63.65%
TCRX T Scan Therapeutics, Inc.	$58.3M	$4.11 Billion 2.04% of portfolio	825,341	Q3 2024 New
LIFE A Tyr Pharma Inc	$53.2M	$3.06 Billion 1.52% of portfolio	1,736,477	Q3 2024 Reduced 10.79%
STOK Stoke Therapeutics, Inc.	$443M	$1.94 Billion 0.96% of portfolio	157,514	Q3 2024 New
TRVI Trevi Therapeutics, Inc.	$239M	$835 Million 0.41% of portfolio	250,000	Q3 2024 Reduced 50.01%
ALLK Allakos Inc.	$107M	$425 Million 0.21% of portfolio	649,957	Q2 2024 Reduced 15.37%

Get notified when there are updates to the investment portfolio of Checkpoint Capital L.P., based on Form 13F filings with the SEC.

Stay updated on Checkpoint Capital L.P. with notifications on news.